Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats
TRLZ, already in clinical trials for cerebellar ataxia, also reduced opioid taking and seeking as well as opioid-derived adverse effects in rats, supporting further study in treating opioid use disorders and pain management.
Authors
- Sonita Wiah
- Saadet Inan (ORCID: https://orcid.org/0000-0003-4510-392X)
- Ewa Galaj (ORCID: https://orcid.org/0000-0002-7180-4378)
- George W. Adamson
- Zheng‐Xiong Xi (ORCID: https://orcid.org/0000-0001-6482-8104)
- Allen B. Reitz (ORCID: https://orcid.org/0000-0003-2780-4044)
- Scott M. Rawls
- Guo‐Hua Bi
Institutions
- National Institute on Drug Abuse (US)
- Colgate University (US)
- Fox Chase Chemical Diversity Center (US)
- Temple University (US)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1111/bph.70206
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00